Literature DB >> 6704664

Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience.

A P Brown, W P Greening, V R McCready, H J Shaw, C L Harmer.   

Abstract

The case records of 235 patients who were treated for differentiated thyroid cancer between 1949 and 1981 were reviewed. Forty-two (18%) had distant metastatic spread outside the neck and received radioiodine (131I) therapy. In cases where the distant spread was confined to the lungs, 54% of patients were alive, free of disease, 10 years after 131I treatment was started. By contrast, no patient with skeletal involvement has survived for 10 years and only one for five years after treatment. A variety of cytotoxic drugs has been tried on an ad hoc basis with no notable success. One patient developed preleukaemia three months after completion of 131I treatment, but no other serious side effects were observed. Factors that influence the behaviour of metastatic thyroid carcinoma are discussed and a possible revised approach to 131I therapy is suggested in the light of these findings.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704664     DOI: 10.1259/0007-1285-57-676-323

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

Review 2.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

3.  Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.

Authors:  L M Haslinghuis; E P Krenning; W W De Herder; A E Reijs; D J Kwekkeboom
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

4.  A different approach to the use of unsealed radionuclides for cancer therapy.

Authors:  V R McCready
Journal:  Eur J Nucl Med       Date:  1995-01

Review 5.  Targeted radionuclide therapy for bone metastases.

Authors:  V J Lewington
Journal:  Eur J Nucl Med       Date:  1993-01

6.  Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma.

Authors:  F Tenenbaum; M Schlumberger; F Bonnin; J Lumbroso; B Aubert; H Benali; C Parmentier
Journal:  Eur J Nucl Med       Date:  1993-12

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

8.  Chest wall resection and reconstruction using titanium micromesh covered with Marlex mesh for metastatic follicular thyroid carcinoma: a case report.

Authors:  Nobuyasu Suganuma; Nobuyuki Wada; Hiromasa Arai; Hirotaka Nakayama; Keita Fujii; Katsuhiko Masudo; Norio Yukawa; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  J Med Case Rep       Date:  2009-06-08

9.  Surgery and survival outcomes of 22 patients with epidural spinal cord compression caused by thyroid tumor spinal metastases.

Authors:  Dan Zhang; Huabin Yin; Zhipeng Wu; Xinghai Yang; Tielong Liu; Jianru Xiao
Journal:  Eur Spine J       Date:  2012-10-18       Impact factor: 3.134

10.  Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?

Authors:  C A Proye; D H Dromer; B M Carnaille; A J Gontier; A Goropoulos; P Carpentier; J Lefebvre; M Decoulx; J L Wemeau; P Fossati
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.